CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is

Aryl optionally substituted by one or more substituents selected from the group consisting of: C_{1-6} alkoxy, halogen, -CN, C_{1-6} alkyl optionally substituted by one or more halogens, -OH, and C_{1-6} alkylCO;

Heteroaryl optionally substituted by C_{1-3} alkyl;

C_{3-7} cycloalkyl;

Heterocyclyl; or

Aryl fused to a heterocyclyl ring;

R^2 is hydrogen or C_{1-6} alkyl;

R^3 is

Hydrogen;

C_{1-6} alkyl optionally substituted by one or more substituents selected from the group consisting of: heterocyclyl (itself optionally substituted by C_{1-6} alkyl), R^7R^8NCO-, R^9CONR^{10}-, C_{1-6} alkoxy, $R^{11}R^{12}N$-, and C_{1-3} alkyl sulfonyl;

C_{3-7} cycloalkyl;

Aryl(CH_2)$_m$- wherein the aryl is optionally substituted by one or more substituents selected from the group consisting of: halogen and C_{1-6} alkoxy;

Aryl fused to a heterocyclyl ring;

Aryl fused to a C_{4-7} cycloalkyl wherein the cycloalkyl is optionally susbstituted by =O;

Heteroaryl(CH_2)$_m$- wherein the heteroaryl is optionally substituted by one or more substituents selected from the group consisting of: C_{1-6} alkyl, halogen and C_{1-6} alkoxy;

Heterocyclyl(CH_2)$_m$- wherein the heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of: C_{1-6} alkylCO, C_{1-6} alkyl;

R^4 is hydrogen or C_{1-6} alkyl;

R^3 and R^4 together with the nitrogen atom to which they are attached may form a heterocyclyl ring, which is optionally substituted by one or more substituents selected from the group consisting of: C_{1-6} alkylCO, C_{1-6}alkoxy, C_{3-7}cycloalkyl, OH, halogen, C_{1-6} alkyl, -(CH_2)$_m$$NR^{13}R^{14}$, -($CH_2$)$_m$$CONR^{15}R^{16}$, -($CH_2$)$_m$$NR^{17}COR^{18}$, heteroaryl, heteroaryl$C_{1-4}$alkyl, heteroarylCO, -$CO_2C_{1-6}$alkyl and C_{1-6}alkoxyC_{1-4}alkyl;

R^5 is hydrogen or C_{1-6} alkyl;

R^6 is hydrogen, C_{1-6} alkyl, C_{1-6}alkoxy, fluorine, chlorine, or bromine;;

m is 0-6;

R^{7-18} all independently represent hydrogen, C_{1-6} alkyl;

R^7 and R^8 together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R^{11} and R^{12} together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R^{13} and R^{14} together with the nitrogen atom to which they are attached may form a heterocyclyl ring.

2. A compound according to claim 1 wherein:

R^1 is

Aryl optionally substituted by one or more substituents selected from the group consisting of: C_{1-6} alkoxy, halogen, -CN, C_{1-6} alkyl optionally substituted by one or more halogens, -OH, and C_{1-6} alkylCO;

Heteroaryl optionally substituted by C_{1-3} alkyl;

C_{3-7} cycloalkyl;

Heterocyclyl; or

Aryl fused to a heterocyclyl ring;

R^2 is hydrogen;

R^3 is

Hydrogen;

C_{1-6} alkyl optionally substituted by one or more substituents selected from the group consisting of: C_{1-3} alkoxy and C_{1-3} alkyl sulfonyl;

C_{3-7} cycloalkyl;

Aryl$(CH_2)_m$- wherein the aryl is optionally substituted by one or more substituents selected from the group consisting of: halogen and C_{1-3} alkoxy;

Aryl fused to a heterocyclyl ring;

Aryl fused to a C_{4-7} cycloalkyl wherein the cycloalkyl is optionally substituted by =O;

Heteroaryl$(CH_2)_m$- wherein the heteroaryl is optionally substituted by one or more substituents selected from the group consisting of: C_{1-6} alkyl, halogen and C_{1-6} alkoxy;

Heterocyclyl$(CH_2)_m$- wherein the heterocyclyl is optionally substituted by C_{1-6} alkyl;

R^4 is hydrogen or C_{1-6} alkyl;

R^3 and R^4 together with the nitrogen atom to which they are attached may form a heterocyclyl ring, which is optionally substituted by one or more substituents selected from the group consisting of: C_{1-6} alkylCO, halogen, C_{1-6} alkyl, $-(CH_2)_mNR^{13}R^{14}$, $-CO_2C_{1-6}$alkyl and C_{1-3}alkoxyC_{1-3}alkyl;

R^5 is hydrogen;

R^6 is hydrogen or C_{1-6} alkyl;

m is 0-6;

R^{13} and R^{14} are independently selected from C_{1-6} alkyl.

3. A compound according to claim 1 or 2 wherein:

R^1 is selected from

Phenyl substituted by one or more substituents selected from the group consisting of: methoxy, halogen, methyl, trifluoromethyl, -OH and C_{1-3} alkylCO;

Heteroaryl optionally substituted by methyl;

Phenyl fused to a heterocyclyl ring.

4. A compound according to any of claims 1 to 3 wherein:

R^3 is selected from:

Hydrogen;

C_{1-4} alkyl optionally substituted by methoxy or methylsulfonyl;

C_{4-6} cycloalkyl;

Phenyl substituted by one or more substituents selected from halogen or methoxy;

Phenyl fused to a 5 membered heterocyclyl ring containing 1 or 2 oxygen atoms;

Phenyl fused to a C_{4-7} cycloalkyl, wherein the cycloalkyl is substituted by =O;

Heteroaryl(CH_2)$_m$- wherein the heteroaryl is optionally substituted by methyl, methoxy or halogen

Heterocyclyl(CH_2)$_m$- wherein the heterocyclyl contains either five or six atoms including one or two heteroatoms selected from nitrogen or oxygen and wherein the heterocyclyl is optionally substituted by C_{1-2} alkyl.

5. A compound according to any of claims 1 to 3 wherein:

R^3 and R^4 together with the nitrogen atom to which they are attached may form a five or six membered heterocyclyl ring, which is optionally substituted by one or more substituents selected from the group consisting of: acetyl, fluoro, methyl, -$N(CH_3)_2$, -CO_2C_{1-2}alkyl and C_{1-3}alkoxyC_{1-3}alkyl.

6. A compound according to any of claims 1 to 5 wherein:

R^5 represents hydrogen.

7. A compound according to any of claims 1 to 6 wherein:

R^6 is methyl.

8. A compound according to any of claims 1 to 7 wherein:

R^1 is 2,3-dihydro-1-benzofuran-4-yl or 4-fluoro-3-(methyloxy)phenyl;

R^2 is hydrogen;

R^3 is selected from:

C_{1-4} alkyl optionally substituted by methoxy or methylsulphonyl;

Pyridyl(CH_2)$_m$-;

Methylpyrazolyl;

Tetrahydropyranyl;

R^4 is hydrogen or methyl;

R^5 is hydrogen;

R^6 is methyl.

9. A compound according to any of claims 1 to 8 wherein:

R^1 is 2,3-dihydro-1-benzofuran-4-yl, 1-methyl-1H-indazol-6-yl or 4-fluoro-3-(methyloxy)phenyl;

R^2 is hydrogen;

In a preferred embodiment R^3 and R^4 together with the nitrogen atom to which they are attached form a morpholinyl, a 2,6-dimethyl-4-morpholinyl, a 3-(ethoxycarbonyl)-1-piperidinyl, a 4-(*N,N*-dimethylamino)1-piperidinyl, a 4-acetyl-1-piperazinyl or a 4-[(2-methyloxy)ethyl]-1-piperazinyl ring.

R^5 is hydrogen;

R^6 is methyl.

10. A compound of formula (I) selected from the group consisting of:

4-{[3-(methyloxy)phenyl]amino}-*N*^{6}-phenyl-3,6-quinolinedicarboxamide,
4-{[3-(methyloxy)phenyl]amino}-6-(4-morpholinylcarbonyl)-3-quinolinecarboxamide,
N^6,*N*^{6}-dimethyl-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,
N^6-1,3-benzothiazol-6-yl-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,
N^6-(1-methyl-1*H*-benzimidazol-5-yl)-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,
4-{[3-(methyloxy)phenyl]amino}-*N*^{6}-3-pyridinyl-3,6-quinolinedicarboxamide,
N^6-[3-(methyloxy)phenyl]-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,
N^6-1,3-benzodioxol-5-yl-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,
4-{[3-(methyloxy)phenyl]amino}-*N*^{6}-(3-oxo-2,3-dihydro-1*H*-inden-5-yl)-3,6-quinolinedicarboxamide,
4-{[3-(methyloxy)phenyl]amino}-*N*^{6}-[6-(methyloxy)-3-pyridinyl]-3,6-quinolinedicarboxamide,
N^6-(4-chlorophenyl)-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,
4-{[3-(methyloxy)phenyl]amino}-6-(1-piperidinylcarbonyl)-3-quinolinecarboxamide,
4-{[3-(methyloxy)phenyl]amino}-*N*^{6}-(1,3-thiazol-2-ylmethyl)-3,6-quinolinedicarboxamide,
N^6-(1,3-dihydro-2-benzofuran-5-yl)-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,
N^6-[(3-methyl-5-isoxazolyl)methyl]-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,

N^6-[(5-chloro-2-pyridinyl)methyl]-4-{[3-(methyloxy)phenyl]amino}-3,6-quinolinedicarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-N~6~,8-dimethyl-N~6~-[2-(methyloxy)ethyl]-3,6-quinolinedicarboxamide
4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(4-morpholinylcarbonyl)-3-quinolinecarboxamide,
8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(4-morpholinylcarbonyl)-3-quinolinecarboxamide,
4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-(4-morpholinylcarbonyl)-3-quinolinecarboxamide,
4-{[4-fluoro-3-(methyloxy)phenyl]amino}-N~6~,8-dimethyl-N~6~-[2-(methyloxy)ethyl]-3,6-quinolinedicarboxamide,
4-{[4-fluoro-3-(methyloxy)phenyl]amino}-N~6~,8-dimethyl-N~6~-[2-(methylsulfonyl)ethyl]-3,6-quinolinedicarboxamide,
6-[(4-acetyl-1-piperazinyl)carbonyl]-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-3-quinolinecarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-N~6~,N~6~,8-trimethyl-3,6-quinolinedicarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-({4-[2-(methyloxy)ethyl]-1-piperazinyl}carbonyl)-3-quinolinecarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-[(2,6-dimethyl-4-morpholinyl)carbonyl]-8-methyl-3-quinolinecarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-{[4-(dimethylamino)-1-piperidinyl]carbonyl}-8-methyl-3-quinolinecarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-N~6~,8-dimethyl-N~6~-(4-pyridinylmethyl)-3,6-quinolinedicarboxamide,
6-[(4-acetyl-1-piperazinyl)carbonyl]-4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-3-quinolinecarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-N~6~-4-pyridinyl-3,6-quinolinedicarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-N~6~-(tetrahydro-2H-pyran-4-yl)-3,6-quinolinedicarboxamide,
4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-N~6~-(1-methyl-1H-pyrazol-5-yl)-3,6-quinolinedicarboxamide.

and pharmaceutically acceptable salts thereof.

11. A process for the preparataion of a compound of formula (I) and pharmaceutically acceptable salts thereof as claimed in any of claims 1 to 10 which comprises:

(A) reacting a compound of formula (II)



(II)

wherein R^1, R^2, R^5 and R^6 are as defined above with a suitable amide coupling agent followed by treatment with an amine of formula R^3R^4NH wherein R^3 and R^4 are as defined above; or

(B) reacting a compound of formula (IV)



(IV)

wherein R^1, R^2, R^5 and R^6 are as defined above and Y represents chlorine, bromine or iodine, with carbon monoxide and an amine of formula R^3R^4NH, wherein R^3 and R^4 are as defined above, in a suitable solvent such as toluene, at a suitable temperature such as the reflux temperature of the solvent, in the presence of a suitable catalyst, such as a palladium catalyst, *e.g.* dichlorobis(triphenylphosphine)palladium(II) and a suitable base, such as triethylamine; or

(C) reacting a compound of formula (XI)



(XI)

wherein R^3, R^4, R^5, R^6 are as defined above and X is halogen, by treatment with an amine of formula R^1R^2NH, wherein R^1 and R^2 are as defined above.

(D) interconversion of a compound of formula (I) into another compound of formula (I); or

(E) deprotecting a protected derivative of a compound of formula (I).

12. A compound or a pharmaceutically acceptable salt thereof, according to any of claims 1 to 10 for use in therapy.

13. A compound or a pharmaceutically acceptable salt thereof, according to any of claims 1 to 10 for use in the treatment or prophylaxis of inflammatory and/or allergic diseases.

14. The use of a compound according to any of claims 1 to 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of inflammatory and/or allergic diseases.

15. A pharmaceutical composition which comprises a compound according to any of claims 1 to 10 optionally with a pharmaceutically acceptable carrier or excipient.

16. A pharmaceutical composition according to claim 15 which is suitable for inhaled administration.

17. A pharmaceutical composition according to claim 15 which is suitable for oral administration.